Antonia Kolovos

Antonia Kolovos

Auto-generated profile, based on publicly available information

Antonia Kolovos

Department of Ophthalmology, Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia, Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Ophthalmology
Verified
Journal Article
Closed access
AQAyub Qassim
Ayub Qassim
SMSean Mullany
Sean Mullany
FAFarshad Abedi
Farshad Abedi
HMHenry Marshall
Henry Marshall
MHMark M. Hassall
Mark M. Hassall
JCJamie E. Craig
Jamie E. Craig

13 August 2022 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
HMHenry Marshall
Henry Marshall
EBElla C Berry
Ella C Berry
STSantiago Diaz Torres
Santiago Diaz Torres
SMSean Mullany
Sean Mullany
JSJoshua Schmidt
Joshua Schmidt
JCJamie E Craig
Jamie E Craig

20 February 2023 in Ophthalmology
Verified
Journal Article
Closed access
IAInas F. Aboobakar
Inas F. Aboobakar
TKTyler G. Kinzy
Tyler G. Kinzy
YZYan Zhao
Yan Zhao
BFBaojian Fan
Baojian Fan
LPLouis R. Pasquale
Louis R. Pasquale
DZDonald J. Zack
Donald J. Zack

1 July 2021 in Ophthalmology Glaucoma
Verified
Journal Article
Closed access
AQAyub Qassim
Ayub Qassim
SMSean Mullany
Sean Mullany
MAMona S. Awadalla
Mona S. Awadalla
MHMark M. Hassall
Mark M. Hassall
TNThi Nguyen
Thi Nguyen
JCJamie E. Craig
Jamie E. Craig

27 August 2024 in Annual Review of Genomics and Human Genetics
Verified
Journal Article
Open access
AKAntonia Kolovos
Antonia Kolovos
MHMark M Hassall
Mark M Hassall
OSOwen M Siggs
Owen M Siggs
ESEmmanuelle Souzeau
Emmanuelle Souzeau
JCJamie E. Craig
Jamie E. Craig
Glaucoma is a clinically heterogeneous disease and the world's leading cause of irreversible blindness. Therapeutic intervention can prevent blindness but relies on early diagnosis, and current clinical risk factors are limited in their ability to predict who will develop sight-threatening glaucoma. The high heritability of glaucoma makes it an ideal substrate for genetic risk prediction, with the bulk of risk being polygenic in nature. Here, we summarize the foundations of glaucoma genetic risk, the development of polygenic risk prediction instruments, and emerging opportunities for genetic risk stratification. Although challenges remain, genetic risk stratification will significantly improve glaucoma screening and management.

24 February 2025 in Ophthalmology
Verified
Journal Article
Open access
AKAntonia Kolovos
Antonia Kolovos
AQAyub Qassim
Ayub Qassim
MHMark M. Hassall
Mark M. Hassall
HMHenry N. Marshall
Henry N. Marshall
JSJoshua Schmidt
Joshua Schmidt
JCJamie E. Craig
Jamie E. Craig
Pseudoexfoliation syndrome (PEX) is a known risk factor for glaucoma, but its individual clinical course ranges from no glaucoma to total blindness. This study investigated whether polygenic risk scores (PRS) built from variants collectively associated with open-angle glaucoma, intraocular pressure (IOP) and vertical cup:disc ratio (VCDR) can stratify individuals with pseudoexfoliation for their risk of glaucoma development. Retrospective multicohort study of two glaucoma registries and one population-based cohort. For the primary analysis, participants (n=828) were classified as PEX-Glaucoma, PEX-Glaucoma Suspect, and PEX-No Glaucoma. For the secondary analysis, a cohort of participants (n=2459) were classified as PEX-Glaucoma, PEX-No Glaucoma, and Unaffected, and an independent cohort of participants (n=3360) were classified as primary open-angle glaucoma (POAG) and POAG-Suspect. Previously published and validated PRS for open-angle glaucoma, IOP and VCDR were expressed as a percentile, decile or tertile of an ancestrally-matched normal population. Multivariable logistic and linear regressions, and survival analyses were performed. Odds of pseudoexfoliative glaucoma, and odds of clinically-relevant outcomes. Participants in the top tertile of the Glaucoma-PRS had greater odds of pseudoexfoliative glaucoma diagnosis (adjusted OR 4.22, 95% CI 2.62 - 6.88, p<0.001), greater odds of bilateral central vision loss (adjusted OR 3.43, 95% CI 1.49 - 8.99, p=0.007), and greater odds of bilateral incisional surgery (adjusted OR 3.35, 95% CI 1.33 - 10.24, p=0.018). Age of pseudoexfoliative glaucoma diagnosis was 1 year younger with each increasing Glaucoma-PRS decile (1.06 years, 95% CI 0.59-1.53, p<0.001). Manifest glaucoma participants with pseudoexfoliation had a comparatively lower Glaucoma-PRS than primary open-angle glaucoma counterparts. PRS for open-angle glaucoma, IOP and VCDR stratify risk of glaucoma development and disease severity amongst individuals with pseudoexfoliation syndrome.